CVS Pharmacy brings ScriptPath label, overview to California
CVS Pharmacy is unveiling its new ScriptPath Prescription Label and Prescription Overview in its 1,160 CVS Pharmacy locations in California this week, the company announced Wednesday.
The new prescription label and overview is part of the ScriptPath Prescription Schedule which the company debuted last October. The system simplifies and organizes key information, increasing a patient’s ability to find and understand their prescription information and dosing instructions.
The new prescription label has clearer directions, larger text for better readability, color-coded icons for different times of day, easy-to-find prescription information, and clear refill details that make reordering prescriptions easy, the company said.
“Fifty percent of patients struggle with understanding how and when to take their prescription medications, and for those with complex prescription regimens it can be even more challenging,” said Troyen Brennan, CVS Health executive vice president and chief medical officer. “By providing them with a clear and concise dosing schedule on their prescription label and overview, along with an easy-to-understand prescription schedule, we can help improve medication adherence and overall health.”
The ScriptPath Prescription Management system uses a tool that automatically reviews all of a patient’s CVS Pharmacy medications and prescribers’ instructions to provide a schedule outlining the most effective times to take medications, CVS Health said.
Deborah Adler, a designer whose work includes Target’s ClearRx prescription packaging system, invented and was the lead designer of the new ScriptPath system. She worked with the CVS Health team to develop the easy-to-understand icons and an intuitive layout for each of the ScriptPath offerings.
The ScriptPath system’s elements are available in English and Spanish. The new label and overview began rolling out in early 2018 and was completed this week, the company said.
Genoa Healthcare expands pharmacies nationwide
Genoa Healthcare continues to expand. The company has increased its footprint with the opening of 12 new pharmacies nationwide, according to a blog post on the company’s website.
The new pharmacies, which opened in the past few months include:
- Manchester, N.H., inside the Mental Health Center of Greater Manchester;
- Hammond, Ind., inside Oak Street Health;
- Farmville, Va., inside Crossroads Community Service Board;
- Bowling Green, Ohio, inside Harbor Behavioral Health;
- Syracuse, N.Y., inside Helio Health;
- Jackson, Miss., inside Hinds Behavioral Health Services;
- Bellingham, Wash., inside Compass Health;
- Morristown, Tenn., inside Helen Ross McNabb Center;
- Syracuse, N.Y., inside Liberty Resources;
- Charlestown, Mass., inside TILL;
- Dayton, Tenn., inside Volunteer Behavioral Health; and
- Greenfield, Mass., inside Clinical & Support Options.
Eisai, Merck get FDA breakthrough therapy designation for Lenvima/Keytruda combination therapy
Eisai and Merck have received the Food and Drug Administration’s blessing for a breakthrough therapy designation for Lenvima (lenvatinib), the orally available kinase inhibitor discovered by Eisai, in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab), the companies announced Tuesday. The combination therapy is indicated for the potential treatment of patients with advanced and/or metastatic non-microsatellite instability high/proficient mismatch repair endometrial carcinoma who have progressed following at least one prior systemic therapy.
This is the third breakthrough therapy designation for Lenvima and the second breakthrough therapy designation for Lenvima in combination with Keytruda, following the breakthrough therapy designation for the combination for advanced and/or metastatic renal cell carcinoma announced in January 2018.
The breakthrough therapy designation is an FDA program intended to expedite development and review of medicines for serious or life-threatening conditions. In order to qualify for this designation, preliminary clinical evidence must demonstrate that the drug may provide substantial improvement over currently available therapy on at least one clinically significant endpoint. The benefits of this designation include more intensive guidance on an efficient clinical development program and access to senior FDA managers and experienced FDA staff to help accelerate review time, as well as eligibility for rolling review and potentially priority review.
“This second breakthrough therapy designation for the Lenvima/Keytruda combination represents another step forward in our collaboration with Eisai and supports the continued evaluation of this combination in more than 11 types of cancer,” said Roy Baynes, Merck Research Laboratories senior vice president and head of global clinical development, chief medical officer. “We will continue to work closely with Eisai to build on the robust data for the lenvima/keytruda combination in advanced endometrial carcinoma in an effort to offer a new option for these patients and potentially help address a critical unmet need.”
“We designed Study 111 to learn as much as we could about the Lenvima/Keytruda combination as efficiently as possible, driven by a sense of urgency to bring forward a potential new treatment option for patients in need,” said Eisai vice president and chief medicine creation officer, oncology business group Takashi Owa. “We are encouraged by the continued activity seen in patients with endometrial carcinoma, and the latest breakthrough therapy designation for Lenvima and Keytruda has strengthened our commitment as part of our human healthcare mission, to expedite the path to ultimately benefitting patients living with endometrial carcinoma as quickly as possible.”